Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its R&D team in Israel studies the combinatorial effects of purified cannabinoids and has recently revealed complex relations between cannabinoid compounds, some of which bare synergistic effects and some antagonistic effects on the viability of gastrointestinal cancer cells.
A heat map of purified cannabinoid combinations showing high synergistic effect in killing gastrointestinal cancer cells only in combinations CB5+CB2. Names of cannabinoids are not present due to IP restrictions.
Natural cannabinoid extracts have been shown to have an entourage effect in various studies in different disease models and clinical studies. The overall view is that the entourage effect leads to better outcomes and purified cannabinoids are more toxic and less effective. However, the underlying combinatorial map of cannabinoids and their effects on cancer cell death remains undiscovered.
Cannabics’ R&D team leverages its High Throughput Screening (HTS) platform to screen the necrotic effects of combinations of purified cannabinoids and builds a matrix to create proprietary new formulations. In this ongoing research on human gastrointestinal cancer cells, purified cannabinoids and their combinations are screened for antitumor effects. Up to date, most of the combinations reveal antagonistic effects and only few show synergisms.
In figure 1, a heat map of purified cannabinoid combinations shows high synergistic effect in killing gastrointestinal cancer cells only in combinations CB5+CB2. Names of cannabinoids are not present due to IP restrictions.
Dr. Eyal Ballan, CTO and Co-Founder, commented, “We examine the efficacy of botanical extracts purified compounds and combinations in order to better understand the potential products under the different regulatory regimes. Our results lead us to new formulations and targets towards clinical validation.”
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cnbxpharma.com.
For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed January 14th, 2020. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.